Long term follow-up of “full metal jacket” of de novo coronary lesions with new generation Zotarolimus-eluting stents

Alessandro Durante, Giovanni Foglia Manzillo, Francesco Burzotta, Carlo Trani, Cristina Aurigemma, Francesco Summaria, Roberto Patrizi, Giovanni Paolo Talarico, Azeem Latib, Filippo Figini, Enrico Romagnoli, Mariarosaria De Vita, Cecilia Fantoni, Luigi My, Claudio Larosa, Alessandro Manzoli, Maurizio Turturo, Andrea Berni, Giovanni Corrado

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Background Diffuse coronary artery disease treatment still remains a challenge for interventional cardiologists and cardiac surgeons. There are few data on full metal jacket (FMJ) stenting, especially with new-generation drug-eluting stents. We aimed to assess the efficacy and safety of FMJ with new-generation Zotarolimus-eluting stents (n-ZES). Methods and results All patients who underwent FMJ with n-ZES (≥ 60 mm stent length) in eleven Italian interventional centers participating in the Clinical Service® project were included in this analysis. The project population consisted of 120 patients and 122 lesions. Mean age was 67 ± 10 years and 95 (79.2%) patients were male. A chronic total occlusion was present in 34 lesions (27.9%). The number of stents implanted per lesion was 2.9 ± 0.8, and the diameter of the stents was 3.0 ± 0.5 mm. Predilation and post-dilatation were performed in 107 (87.7%) and 92 (75.4%) patients, respectively. At 41 ± 21 month follow-up there were 2 patients with subacute definite stent thrombosis, 6 patients (5.0%) had cardiac death and 5 patients (4.2%) had non-fatal myocardial infarction. Seven patients (5.8%) underwent clinically-driven target lesion revascularization. Fourteen patients (11.7%) had at least one major adverse cardiac event. Conclusion The treatment of diffuse coronary artery disease with FMJ stenting with n-ZES appears to be effective and safe. Late and very-late ST does not seem to be an issue and the rate of restenosis and of major cardiac adverse events after more than 3-year follow-up is rather low.

Original languageEnglish (US)
Pages (from-to)1008-1012
Number of pages5
JournalInternational Journal of Cardiology
StatePublished - Oct 15 2016
Externally publishedYes


  • DES
  • Drug eluting stent
  • Full metal jacket
  • PCI
  • ZES

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Long term follow-up of “full metal jacket” of de novo coronary lesions with new generation Zotarolimus-eluting stents'. Together they form a unique fingerprint.

Cite this